So here’s a look at America’s prospects for 2012. The economy might be headed for a stronger growth track, but there are least three potential obstacles to watch for: Europe, China and political gridlock.
US seems to have de-coupled with Europe and its troubles.
First the positive signs, of which there are plenty: the jobs market is looking up, housing sales and construction have been showing recent signs of improvement, business sales and profits are rising.
It appears that the Life Science and the IT industry will be the leading sectors in 2012.
US Pharma and the med tech companies are cash rich. All life science M&A activity has been strong.
Now, as the FDA starts showing the improvements in their processes. The Med tech industry is showing signs of a boom. See the trend in the early stage investments in the med tech sector from 1994 to 2011. The amount of investments is going up since its peak in 2008.
The JP Morgan Health Care Conference meeting in San Francisco will be attended by entrepreneurs and investors from the US and abroad.The health care need in the treatments of Obesity, Diabetes, Orthopedic and Spine Implants, Cardio-Vascular products, Personalized e-health, Diagnostics
What is holding back the surge in life Science Industry is: US FDA
Industry experts suggest that: FDA needs to "not play physician" and let physicians plan the patient treatments and decide what is best for their patients. The European MDD (Medical Device Directive) is the fair example. If the FDA regulators understand that health care is subjective and many patients are being deprived of new technology because of the red tape at the FDA. Bottom line, if companies have a ISO 13585 certification, FDA should approve the product in the US market. This will enable the patients have access to a wide variety of treatment options and it will be great for the life science industry.
No comments:
Post a Comment